PortfoliosLab logoPortfoliosLab logo
GERM vs. GNOM
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

GERM vs. GNOM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Treatments, Testing and Advancements ETF (GERM) and Global X Genomics & Biotechnology ETF (GNOM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


GERM

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
0.00%
3Y*
5Y*
10Y*

GNOM

1D
0.90%
1M
12.22%
YTD
14.90%
6M
11.42%
1Y
61.83%
3Y*
2.88%
5Y*
-11.06%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

GERM vs. GNOM - Yearly Performance Comparison


2026 (YTD)20252024
GERM
Amplify Treatments, Testing and Advancements ETF
0.00%0.00%0.00%
GNOM
Global X Genomics & Biotechnology ETF
14.90%18.65%-11.57%

GERM vs. GNOM - Sectors Allocation Comparison


Sectors
GERM
GNOM

Healthcare

99.3%
99.7%

Financial Services

0.4%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

0.3%

Utilities

-

-

Healthcare

GERM
99.3%
GNOM
99.7%

Financial Services

GERM
0.4%
GNOM

-

Basic Materials

GERM

-

GNOM

-

Communication Services

GERM

-

GNOM

-

Consumer Cyclical

GERM

-

GNOM

-

Consumer Defensive

GERM

-

GNOM

-

Energy

GERM

-

GNOM

-

Industrials

GERM

-

GNOM

-

Real Estate

GERM

-

GNOM

-

Technology

GERM

-

GNOM
0.3%

Utilities

GERM

-

GNOM

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GERM vs. GNOM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GERM

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.


GNOM
GNOM Risk / Return Rank: 6868
Overall Rank
GNOM Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
GNOM Sortino Ratio Rank: 7474
Sortino Ratio Rank
GNOM Omega Ratio Rank: 6363
Omega Ratio Rank
GNOM Calmar Ratio Rank: 7171
Calmar Ratio Rank
GNOM Martin Ratio Rank: 5858
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERM vs. GNOM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and Global X Genomics & Biotechnology ETF (GNOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


GERMGNOMDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.36

Calmar ratioReturn relative to maximum drawdown

3.42

Martin ratioReturn relative to average drawdown

9.81

GERM vs. GNOM - Sharpe Ratio Comparison


Loading charts...

Drawdowns

GERM vs. GNOM - Drawdown Comparison

The maximum GERM drawdown since its inception was 0.00%, smaller than the maximum GNOM drawdown of -75.00%. Use the drawdown chart below to compare losses from any high point for GERM and GNOM.


Loading charts...

Drawdown Indicators


GERMGNOMDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-75.00%

+75.00%

Max Drawdown (1Y)

Largest decline over 1 year

0.00%

-18.17%

+18.17%

Max Drawdown (3Y)

Largest decline over 3 years

-44.24%

Max Drawdown (5Y)

Largest decline over 5 years

-72.29%

Current Drawdown

Current decline from peak

0.00%

-52.52%

+52.52%

Average Drawdown

Average peak-to-trough decline

0.00%

-40.63%

+40.63%

Ulcer Index

Depth and duration of drawdowns from previous peaks

0.00%

6.32%

-6.32%

Volatility

GERM vs. GNOM - Volatility Comparison

The current volatility for Amplify Treatments, Testing and Advancements ETF (GERM) is 0.00%, while Global X Genomics & Biotechnology ETF (GNOM) has a volatility of 9.34%. This indicates that GERM experiences smaller price fluctuations and is considered to be less risky than GNOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GERMGNOMDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.00%

9.34%

-9.34%

Volatility (6M)

Calculated over the trailing 6-month period

0.00%

20.57%

-20.57%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

27.29%

-27.29%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

33.68%

-33.68%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

34.17%

-34.17%

GERM vs. GNOM - Expense Ratio Comparison

GERM has a 0.68% expense ratio, which is higher than GNOM's 0.50% expense ratio.


Dividends

GERM vs. GNOM - Dividend Comparison

GERM has not paid dividends to shareholders, while GNOM's dividend yield for the trailing twelve months is around 1.20%.


PositionTTM202520242023202220212020
GERM
Amplify Treatments, Testing and Advancements ETF
0.00%0.00%0.00%0.00%0.00%0.00%0.00%
GNOM
Global X Genomics & Biotechnology ETF
1.20%1.37%0.00%0.00%0.00%0.03%0.14%

Frequently Asked Questions


GNOM has higher volatility (9.34%) compared to GERM (0.00%). In terms of maximum drawdown, GERM dropped 0.00% vs GNOM's -75.00%.

On 1-year performance, GNOM leads with 61.83% vs 0.00% for GERM. On fees, GNOM is cheaper at 0.50% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 1-year period, GNOM has performed better with a 61.83% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

GNOM is cheaper with a 0.50% expense ratio, compared with 0.68% for GERM.

GNOM has the higher dividend yield at 1.20%, compared with 0.00% for GERM.

GERM tracks Prime Treatments, Testing and Advancements Index, while GNOM tracks Solactive Genomics Index. They also come from different issuers: Amplify and Global X. Their fees differ too: 0.68% for GERM and 0.50% for GNOM.

Portfolio Optimizer

Find the right allocation for GERM and GNOM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer